ABBV Secures EU Approval for Atogepant as Acute Migraine Treatment
What happened
AbbVie received European Union regulatory approval for atogepant as a treatment for acute migraine in adults. The approval expands the drug's European label beyond its existing preventive migraine indication. Atogepant, marketed as Qulipta in the United States, belongs to the CGRP receptor antagonist class. The EU green light opens AbbVie to a broader migraine patient population across European markets, where the drug was previously limited to episodic and chronic migraine prevention.
The QL Read
QuantLogix composite for ABBV sits at 55/100 against a share price of $212.93, down 0.72% on the session. Analysts may revisit consensus revenue estimates for the neuroscience segment following the expanded EU label.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.